[IDH、TERT and 1p/19q predicting clinical outcomes in patients with anaplastic oligodendroglioma]
- PMID: 31269600
- DOI: 10.3760/cma.j.issn.0376-2491.2019.25.011
[IDH、TERT and 1p/19q predicting clinical outcomes in patients with anaplastic oligodendroglioma]
Abstract
Objective: To investigate the prognostic values of IDH, TERT and 1p/19q in patients with anaplastic oligodendroglioma. Methods: In the study, 66 patients with pathological diagnosis of anaplastic oligodendroglioma were enrolled (The First Affiliated Hospital of Zhengzhou University 2011 to 2016 years). Kaplan-Meier method was used to calculate the survival rates. Log-rank was used to calculate the differences in group. Chi-square testwas used tocalculate the differences in common factor group. Cox regression model was used to conduct multivariate analysis. Results: The median survival time of IDH-wt and IDH-mt subgroups were 16.10 and 42.00 months with statistical significance (P=0.001). The median survival time of 1p/19q codeleted and 1p/19q noncodeleted subgroups were 42.00 and 22.40 months with statistical significance (P=0.012). IDH-mt and 1p/19q codeleted predicted better survivals compared with IDH-wt and 1p/19q noncodeleted (P=0.001). And IDH-mt and 1p/19q noncodeleted predicted better survivals compared with IDH-wt and 1p/19q noncodeleted (P=0.041), too. Multivariate survival analysis demonstrated that Molecular groups was an independent factor to evaluate the prognosis of anaplastic oligodendroglioma (P=0.008). Conclusion: IDH-mtand (or) 1p/19q codeletedpredicted better survivals in patients with anaplastic oligodendroglioma. IDH and 1p/19q deleted might be a biomarker for predicting prognosis of patients with anaplastic oligodendroglioma.
目的: 研究异柠檬酸脱氢酶(IDH)、端粒酶逆转录酶基因启动子(TERT)及1p/19q的突变情况对间变性少突胶质瘤患者临床预后的影响。 方法: 研究样本入组选取了2011至2016年在郑州大学第一附属医院确诊的间变性少突胶质瘤患者,收集临床资料,随访得到生存资料,共计纳入66例。χ(2)检验用来分析IDH、TERT及1p/19q和各个临床因素之间的关系,采用Kaplan-Meier法进行生存分析,不同组间生存率差异的比较采用Log rank检验。Cox比例风险模型进行独立预后影响因素的多因素分析。 结果: IDH-wt和IDH-mt两组患者的中位生存期分别为16.10及42.00个月,差异有统计学意义(P=0.001);1p/19q非联合缺失和1p/19q联合缺失两组的中位生存期分别为22.40及42.00个月,差异有统计学意义(P=0.012);而TERT-wt和TERT-mt两组的中位生存期分别为20.00及36.00个月,差异无统计学意义(P=0.176)。不同分子病理学分型分组显示,IDH-mt和1p/19q联合缺失组比IDH-wt和1p/19q非联合缺失组(P=0.001)(中位生存期42.00个月比16.05个月)(P=0.001)、IDH-mt和1p/19q非联合缺失组比IDH-wt和1p/19q非联合缺失组(P=0.041)(中位生存期36.50个月比16.05个月)(P=0.041)组间差异有统计学意义。多因素分析显示,分子病理学分型是影响间变性少突胶质瘤患者预后的独立影响因素(P=0.008)。 结论: 具有IDH和(或)1p/19q联合缺失的间变性少突胶质瘤患者有着较好的临床预后,IDH和1p/19q突变情况可作为潜在的预测间变性少突胶质瘤患者预后的标志物。.
Keywords: Anaplastic oligodendroglioma; IDH; Prognosis; TERT,1p/19q.
Similar articles
-
Loss of H3K27 trimethylation is frequent in IDH1-R132H but not in non-canonical IDH1/2 mutated and 1p/19q codeleted oligodendroglioma: a Japanese cohort study.Acta Neuropathol Commun. 2021 May 21;9(1):95. doi: 10.1186/s40478-021-01194-7. Acta Neuropathol Commun. 2021. PMID: 34020723 Free PMC article.
-
The correlation analysis of TERT promoter mutations with IDH1/2 mutations and 1p/19q detected in human gliomas.Medicine (Baltimore). 2022 Jul 22;101(29):e29668. doi: 10.1097/MD.0000000000029668. Medicine (Baltimore). 2022. PMID: 35866817 Free PMC article.
-
Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience.J Neurooncol. 2013 Aug;114(1):85-91. doi: 10.1007/s11060-013-1152-0. Epub 2013 May 17. J Neurooncol. 2013. PMID: 23681562
-
Molecular background of oligodendroglioma: 1p/19q, IDH, TERT, CIC and FUBP1.CNS Oncol. 2015;4(5):287-94. doi: 10.2217/cns.15.32. Epub 2015 Nov 6. CNS Oncol. 2015. PMID: 26545048 Free PMC article. Review.
-
Oligodendrogliomas: new insights from the genetics and perspectives.Curr Opin Oncol. 2012 Nov;24(6):687-93. doi: 10.1097/CCO.0b013e328357f4ea. Curr Opin Oncol. 2012. PMID: 22913971 Review.
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical